Please login to the form below

Not currently logged in
Email:
Password:

mis-marketing

This page shows the latest mis-marketing news and features for those working in and with pharma, biotech and healthcare.

Double win for J&J's schizophrenia franchise

Double win for J&J's schizophrenia franchise

Johnson &Johnson (J&J) will not have to pay a $1.2bn penalty for alleged mis-selling of its schizophrenia drug Risperdal in the US, according to a court ruling. ... Two years ago, a $1.2bn fine was levied on J&J and its Janssen Pharma unit after a jury

Latest news

  • Takeda CEO admits to Blopress mis-marketing Takeda CEO admits to Blopress mis-marketing

    Takeda CEO admits to Blopress mis-marketing. Campaign used graph indicating drug was superior to Pfizer’ s Norvasc. ... The mis-marketing stemmed from a trial initially reported at a medical conference in 2006 and subsequently published in the journal

  • J&J to pay $181m to settle Risperdal off-label promotion lawsuits in the US J&J to pay $181m to settle Risperdal off-label promotion lawsuits in the US

    Company's Janssen subsidiary looks to draw a line under mis-marketing claims filed in 36 US states. ... J&J also paid a settlement charge of $158m to the state of Texas in January, 2012, for a case that again involved allegations concerning the marketing

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics